Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Propicillin is a semisynthetic, acid-stable penicillin antibiotic primarily used to treat streptococcal infections. It is structurally and functionally similar to benzylpenicillin but is distinguished by its resistance to gastric acid, allowing for oral administration as the potassium salt. Like other penicillins, it exerts its antibacterial effect by binding to and inactivating penicillin-binding proteins (PBPs) on the inner membrane of bacterial cell walls. This action disrupts the cross-linking of peptidoglycan chains necessary for cell wall strength and rigidity, leading to bacterial cell lysis. However, propicillin is not resistant to penicillinase (beta-lactamase), limiting its effectiveness against beta-lactamase-producing organisms[1][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on propicillin.